The global wound care biologics market is projected to reach USD 2.4 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 5.4% during the forecast period. The wound care biologics market is driven by the growing prevalence of diseases & conditions affecting wound healing capabilities and the increasing number of surgical procedures across the globe.

The top players in this market are Smith & Nephew plc (UK), Organogenesis Inc. (US), MIMEDX (US), Integra LifeSciences (US), and Stryker Corporation (US). These players lead the market because of their extensive product portfolios. These players have also invested in organic strategies such as product launches and regulatory approvals and inorganic growth strategies such as partnerships, acquisitions, and agreements to maintain their market shares.